PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Prednisolone - Inflammatory bowel disease
PAD Profile : Prednisolone - Inflammatory bowel disease
Keywords :
IBD, chronic bowel disorders, UC, Ulcerative colitis, predsol
Brand Names Include :
Predfoam
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
03 June 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.
If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.
13 March 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN does not recommend Prednisolone foam enemas as a treatment option for patients with active Ulcerative Colitis
Prednisolone foam enemas will be considered BLACK, for new patients, on the traffic light system
People who are currently receiving prednisolone foam enema should have the option to continue therapy from their usual prescriber until they and their clinicians consider it appropriate to stop.
Primary care prescribers should consider switching patients to budesonide rectal foam and for all new patients.
Associated BNF Codes
01. Gastro-Intestinal System
01.05.02. Corticosteroids